Ophthalmology has become one of private equity’s favorite corners of American medicine, and the consolidation is happening fast enough that many patients won’t notice the change until they’re already sitting in the exam chair.
Why Eye Care Became a Target
The appeal is straightforward. Ophthalmology practices generate reliable, high-margin revenue through procedures like cataract surgery, LASIK, and retinal treatments – procedures that are largely elective or age-driven, meaning demand doesn’t crater during economic downturns. An aging population guarantees a steady pipeline of patients. Add in the fact that many ophthalmology practices are still physician-owned, often by a single doctor or a small partnership nearing retirement age, and private equity firms see a fragmented market ripe for assembly.
The transaction structure that makes these deals attractive is called a platform-and-bolt-on model. A private equity group acquires one established regional practice – the “platform” – at a premium valuation, then uses it as the base to acquire smaller surrounding clinics at lower multiples. Over a holding period of three to seven years, the consolidated group becomes large enough to command better insurance reimbursement rates, negotiate bulk pricing on surgical equipment and supplies, and eventually sell to a larger buyer or take public. The math works if you can keep acquiring cheaply and exit at scale.
Ophthalmologists approaching retirement are particularly receptive. A solo practitioner who built a practice over three decades faces a real dilemma: sell to a hospital system and lose autonomy, recruit a younger partner who may not have the capital to buy in fairly, or take the private equity offer that often comes with a meaningful upfront payment and an offer to stay on as a salaried physician. For physicians in their late fifties who haven’t built a separate investment portfolio outside the practice, that check can look like the retirement plan they never got around to building.
The deals are also quiet by design. Private equity acquisitions of medical practices do not require antitrust review below certain revenue thresholds, and most transactions in the ophthalmology space fall well below the Federal Trade Commission’s reporting requirements. A regional practice with three or four locations changes ownership, a new management company logo appears on the billing paperwork, and that’s roughly where the public trail ends.
How the Consolidation Actually Works on the Ground
When a private equity-backed management services organization, or MSO, acquires an eye care practice, the legal structure is carefully engineered around state laws that prohibit corporations from directly employing physicians. The MSO technically owns the administrative and operational side of the business – the real estate lease, the equipment, the billing department, the staff – while a physician-owned professional corporation retains the clinical license. In practice, the management contract gives the MSO extensive control over scheduling, staffing levels, supply purchasing, and fee structures. The physician owns the medical decisions; the MSO owns almost everything else that determines how profitable those decisions are.
Staff at acquired practices frequently report pressure to increase patient volume and reduce time per appointment. Cataract surgery, which can be performed in roughly 15 minutes by an experienced surgeon, becomes a production metric rather than a clinical event. Some practices shift toward a higher volume of add-on procedures – premium intraocular lens upgrades, for instance – where the out-of-pocket cost to patients is significant and the margin to the practice is high. The physician isn’t necessarily acting unethically, but the operational incentives built into PE-owned practices create conditions where upselling becomes structurally normalized.
Staffing is where consolidation shows its roughest edges. Back-office functions get centralized quickly after acquisition – billing, insurance verification, scheduling often move to a shared services center that may be in a different state. Local administrative employees who built relationships with patients and knew the quirks of the local insurance market are frequently let go. What replaces them is a standardized system optimized for throughput. Patient wait times for routine appointments can lengthen as volume increases faster than clinical hiring.
The geographic dimension matters too. When a private equity group assembles a regional ophthalmology network, the goal is market coverage – having enough locations that insurers cannot exclude the network without angering a significant portion of their enrollees. Once that threshold is crossed, the consolidated group has real leverage in contract negotiations. That leverage eventually translates to higher reimbursement rates, which sounds good but tends to flow back to the investor, not to lower costs for patients or better pay for clinical staff.
This pattern – consolidation driving up reimbursement without improving outcomes – is well documented across other medical specialties. Regional nephrology practices selling to dialysis giants followed nearly the same arc: fragmented independent providers, targeted acquisition campaigns, reimbursement leverage, and patient complaints about access and continuity emerging years after the deals closed. Ophthalmology is several years behind nephrology on that timeline, but the trajectory is recognizable.
The Tension That Won’t Resolve Itself
Physicians who sell describe a honeymoon period – typically the first one to three years – where the administrative burden genuinely lightens, the check has cleared, and the new owners are still working to integrate the practice smoothly. The friction tends to arrive in year two or three, when cost-cutting targets hit staffing ratios, when the original earnout conditions require hitting volume metrics, or when the PE firm begins positioning for a secondary sale and wants to maximize EBITDA before exit. At that point, the physician is often contractually locked in and operationally dependent on infrastructure the MSO controls.
State medical boards are beginning to ask sharper questions about the MSO model’s compatibility with physician independence requirements, and a small number of state attorneys general have opened investigations into whether certain management contracts cross the line from administrative support into de facto corporate practice of medicine. None of those inquiries have produced major enforcement actions yet. The deals keep closing, the platforms keep growing, and ophthalmologists in their mid-fifties keep getting calls from practice brokers asking if they’ve ever thought seriously about what their practice is worth.
